Marksans Pharma Ltd

NSE: MARKSANS · BSE: 524404 · Pharmaceuticals & Biotechnology · 30 announcements

Share price: ₹326.05
Market cap: ₹14,775 Cr
Revenue (annual): ₹2,951 Cr
Net profit (annual): ₹417.9 Cr
P/E (TTM): 28.6×Sector 47.4×
Promoter holding: 43.87%+0.00% QoQ
FII holding: 17.47%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 6 Other Announcement 4 Financial Results 3 Acquisition 3 Merger & Restructuring 2 Board Meeting Date 2 Annual General Meeting 2 Results Update 1 Promoter Selling (Off-Market) 1 Employee Stock Options 1 Dividend 1 Credit Rating 1 Business Update 1 Board Meeting Outcome 1 Annual Report 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

20 Jul 2026 17:15 IST BSE

Merger & Restructuring

Marksans Pharma Merger & Restructuring

Marksans Pharma Ltd. has completed the acquisition of 100% share capital of German entity ABCnow GmbH. This strategic move marks the company's expansion into the German market.

Read the filing ↗

8 Jul 2026 10:07 IST BSE

Merger & Restructuring

Marksans Pharma Merger & Restructuring Worth ₹9.64 Cr

Marksans Pharma signed a definitive agreement to acquire ABCnow GmbH for €892,384 (≈ 9.64 Crore INR). The deal, closing by 31 July 2026, gives Marksans a foothold in Europe.

Value: ₹9.64 Cr

Read the filing ↗